181 related articles for article (PubMed ID: 24910925)
1. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.
Santoro AB; Vargens DD; Barros Filho Mde C; Bulzico DA; Kowalski LP; Meirelles RM; Paula DP; Neves RR; Pessoa CN; Struchine CJ; Suarez-Kurtz G
Br J Clin Pharmacol; 2014 Nov; 78(5):1067-75. PubMed ID: 24910925
[TBL] [Abstract][Full Text] [Related]
2. Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer.
Vargens DD; Neves RR; Bulzico DA; Ojopi EB; Meirelles RM; Pessoa CN; Prado CM; Gonçalves PA; Leal VL; Suarez-Kurtz G
Pharmacogenet Genomics; 2011 Jun; 21(6):341-3. PubMed ID: 21317830
[TBL] [Abstract][Full Text] [Related]
3. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
4. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma.
Hoftijzer HC; Heemstra KA; Visser TJ; le Cessie S; Peeters RP; Corssmit EP; Smit JW
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1527-33. PubMed ID: 21715540
[TBL] [Abstract][Full Text] [Related]
5. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
7. [Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma].
Reverter JL; Colomé E
Endocrinol Nutr; 2011 Feb; 58(2):75-83. PubMed ID: 21247815
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
9. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
[TBL] [Abstract][Full Text] [Related]
10. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
[TBL] [Abstract][Full Text] [Related]
11. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
12. Association between genetic polymorphism and levothyroxine bioavailability in hypothyroid patients.
Arici M; Oztas E; Yanar F; Aksakal N; Ozcinar B; Ozhan G
Endocr J; 2018 Mar; 65(3):317-323. PubMed ID: 29321381
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adequacy of levo-thyroxine dosage in patients with differentiated thyroid carcinoma: correlation between morning and afternoon TSH determination.
Conte L; Monti E; Gay S; Marroni P; Adorno A; Mittica M; Mussap M; Giusti M
J Endocrinol Invest; 2018 Oct; 41(10):1193-1197. PubMed ID: 29476411
[TBL] [Abstract][Full Text] [Related]
14. L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer: Effect of a novel UGT1 marker, rs11563250A > G.
Santoro AB; Struchiner CJ; Suarez-Kurtz G
Br J Clin Pharmacol; 2016 Nov; 82(5):1402-1403. PubMed ID: 27527610
[No Abstract] [Full Text] [Related]
15. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
16. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
17. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
[TBL] [Abstract][Full Text] [Related]
18. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
19. Determination of Frequency of Type 2 Deiodinase Thr92Ala Polymorphism (rs225014) in
Gawandi S; Jothivel K; Kulkarni S
Indian J Nucl Med; 2024; 39(1):24-28. PubMed ID: 38817730
[TBL] [Abstract][Full Text] [Related]
20. Deiodinases, Organic Anion Transporter Polypeptide Polymorphisms, and Thyroid Hormones in Patients with Myocardial Infarction.
Brozaitiene J; Skiriute D; Burkauskas J; Podlipskyte A; Jankauskiene E; Serretti A; Mickuviene N
Genet Test Mol Biomarkers; 2018 Apr; 22(4):270-278. PubMed ID: 29641285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
